The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Class-Sparing Regimens for Initial Treatment of HIV-1 Infection
Open accessAbstract
BACKGROUND: The use of either efavirenz or lopinavir-ritonavir plus two nucleoside reverse-transcriptase inhibitors (NRTIs) is recommended for initial therapy for patients with human immunodeficiency virus type 1 (HIV-1) infection, but which of the two regimens has greater efficacy is not known. The alternative regimen of lopinavir-ritonavir plus efavirenz may prevent toxic effects associated with NRTIs. METHODS: In an open-label study, we compared three regimens for initial therapy: efavirenz plus two NRTIs (efavirenz group), lopinavir-ritonavir plus two NRTIs (lopinavir-ritonavir group), and lopinavir-ritonavir plus efavirenz (NRTI-sparing group). We randomly assigned 757 patients with a median CD4 count of 191 cells per cubic millimeter and a median HIV-1 RNA level of 4.8 log10 copies per milliliter to the three groups. RESULTS: At a median follow-up of 112 weeks, the time to virologic failure was longer in the efavirenz group than in the lopinavir-ritonavir group (P=0.006) but was not significantly different in the NRTI-sparing group from the time in either of the other two groups. At week 96, the proportion of patients with fewer than 50 copies of plasma HIV-1 RNA per milliliter was 89% in the efavirenz group, 77% in the lopinavir-ritonavir group, and 83% in the NRTI-sparing group (P=0.003 for the comparison between the efavirenz group and the lopinavir-ritonavir group). The groups did not differ significantly in the time to discontinuation because of toxic effects. At virologic failure, antiretroviral resistance mutations were more frequent in the NRTI-sparing group than in the other two groups. CONCLUSIONS: Virologic failure was less likely in the efavirenz group than in the lopinavir-ritonavir group. The virologic efficacy of the NRTI-sparing regimen was similar to that of the efavirenz regimen but was more likely to be associated with drug resistance. (ClinicalTrials.gov number, NCT00050895 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UPDATE ON DRUG RESISTANCE MUTATIONS IN HIV-1
&NA; (2001) · Infectious Diseases in Clinical Practice · doi:10.1097/00019048-200106000-00020 · Cited by 1,660
Chesney, M. A., Ickovics, J. R., Chambers, D. B., Gifford, A. L., Neidig, J., Zwickl, B., Wu, A. W., & PATIENT CARE COMMITTEE & ADHERENCE (2000) · AIDS Care · doi:10.1080/09540120050042891 · Cited by 1,428
Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society–USA Panel
Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S. G., Schooley, R. T., Jacobsen, D. M., Thompson, M. A., Carpenter, C. C. J., Fischl, M. A., Gazzard, B. G., et al. (2006) · JAMA · doi:10.1001/jama.296.7.827 · Cited by 1,033
Staszewski, S., Morales-Ramirez, J., Tashima, K. T., Rachlis, A., Skiest, D., Stanford, J., Stryker, R., Johnson, P., Labriola, D. F., Farina, D., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412501 · Cited by 993
Treatment for Adult HIV Infection: 2004 Recommendations of the International AIDS Society-USA Panel
Yeni, P. G., Hammer, S. M., Hirsch, M. S., Saag, M. S., Schechter, M., Carpenter, C. C. J., Fischl, M. A., Gatell, J. M., Gazzard, B. G., Jacobsen, D. M., et al. (2004) · JAMA · doi:10.1001/jama.292.2.251 · Cited by 737
Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection
Walmsley, S., Bernstein, B., King, M., Arribas, J., Beall, G., Ruane, P., Johnson, M., Johnson, D., Lalonde, R., Japour, A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012354 · Cited by 647
Carr, A., Miller, J., Law, M., & Cooper, D. A. (2000) · AIDS · doi:10.1097/00002030-200002180-00001 · Cited by 630
Gulick, R. M., Ribaudo, H. J., Shikuma, C. M., Lustgarten, S., Squires, K. E., Meyer, W. A., Acosta, E. P., Schackman, B. R., Pilcher, C. D., Murphy, R. L., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031772 · Cited by 522
Self-citationMallal, S. A., John, M., Moore, C. B., James, I. R., & McKinnon, E. J. (2000) · AIDS · doi:10.1097/00002030-200007070-00002 · Cited by 510
Update of the drug resistance mutations in HIV-1: Fall 2005.
Johnson, V. A., Brun‐Vézinet, F., Clotet, B., Conway, B., Kuritzkes, D. R., Pillay, D., Schapiro, J., Telenti, A., & Richman, D. D. (2005) · PubMed · Cited by 333
Cited by
Thompson, M. A., Aberg, J. A., Hoy, J. F., Telenti, A., Benson, C., Cahn, P., Eron, J. J., Günthard, H. F., Hammer, S. M., Reiss, P., et al. (2012) · JAMA · doi:10.1001/jama.2012.7961 · Cited by 2,469
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089
Worm, S. W., Sabin, C., Weber, R., Reiss, P., El‐Sadr, W., Dabis, F., De Wit, S., Law, M., Monforte, A. D., Friis‐Møller, N., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/649897 · Cited by 648
HIV protease inhibitors: a review of molecular selectivity and toxicity
Wang, Y., Lv, Z., & Chu, Y. (2015) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s79956 · Cited by 450
Antiretroviral therapy and management of HIV infection
Volberding, P. A., & Deeks, S. G. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60676-9 · Cited by 449
Cahn, P., Madero, J. S., Arribas, J. R., Antinori, A., Ortiz, R., Clarke, A. E., Hung, C.-C., Rockstroh, J. K., Girard, P.-M., Sievers, J., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32462-0 · Cited by 387
Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine
Cihlar, T., & Ray, A. S. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.09.014 · Cited by 375
Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance
Wensing, A. M. J., van Maarseveen, N. M., & Nijhuis, M. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.10.003 · Cited by 339
Daar, E. S., Tierney, C., Fischl, M. A., Sax, P. E., Mollan, K., Budhathoki, C., Godfrey, C., Jahed, N. C., Myers, L., Katzenstein, D., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-7-201104050-00316 · Cited by 312
Self-citationLucas, G. M., Ross, M. J., Stock, P. G., Shlipak, M. G., Wyatt, C. M., Gupta, S. K., Atta, M. G., Wools-Kaloustian, K. K., Pham, P. A., Bruggeman, L. A., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu617 · Cited by 310
Barth, R. E., van der Loeff, M. F. S., Schuurman, R., Hoepelman, A. I., & Wensing, A. M. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70328-7 · Cited by 310
Torriani, F. J., Komarow, L., Parker, R. A., Cotter, B. R., Currier, J. S., Dubé, M. P., Fichtenbaum, C. J., Gerschenson, M., Mitchell, C. K. C., Murphy, R. L., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.04.049 · Cited by 300
Self-citationAzijn, H., Tirry, I., Vingerhoets, J., de Béthune, M.-P., Kraus, G., Boven, K., Jochmans, D., Van Craenenbroeck, E., Picchio, G., & Rimsky, L. T. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00986-09 · Cited by 293
Current status and challenges of antiretroviral research and therapy
Esté, J. A., & Cihlar, T. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.10.007 · Cited by 277
Molina, J.-M., Andrade-Villanueva, J., Echevarria, J., Chetchotisakd, P., Corral, J., David, N., Moyle, G., Mancini, M., Percival, L., Yang, R., et al. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181c990bf · Cited by 254
Haubrich, R. H., Riddler, S. A., DiRienzo, A. G., Komarow, L., Powderly, W. G., Klingman, K., Garren, K. W., Butcher, D. L., Rooney, J. F., Haas, D. W., et al. (2009) · AIDS · doi:10.1097/qad.0b013e32832b4377 · Cited by 254
Self-citationFull-length HIV-1 Gag determines protease inhibitor susceptibility within in-vitro assays
Gupta, R. K., Kohli, A., McCormick, A. L., Towers, G. J., Pillay, D., & Parry, C. M. (2010) · AIDS · doi:10.1097/qad.0b013e3283398216 · Cited by 71
Efavirenz: what is known about the cellular mechanisms responsible for its adverse effects
Apostolova, N., Blas-Garcia, A., Galindo, M. J., & Esplugues, J. V. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.07.016 · Cited by 49
Deiss, R. G., Mesner, O., Agan, B. K., Ganesan, A., Okulicz, J. F., Bavaro, M., Lalani, T., O'Bryan, T. A., Bebu, I., & Macalino, G. E. (2016) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12975 · Cited by 38
Gregson, J., Rhee, S. Y., Datir, R., Pillay, D., Perno, C. F., Derache, A., Shafer, R. S., & Gupta, R. K. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz631 · Cited by 24
Metadata
- Authors
- Riddler, S. A., Haubrich, R., DiRienzo, A. G., Peeples, L., Powderly, W. G., Klingman, K. L., Garren, K. W., George, T., Rooney, J. F., Brizz, B., Lalloo, U. G., Murphy, R. L., Swindells, S., Havlir, D., & Mellors, J. W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-15
- Volume
- 358
- Issue
- 20
- Pages
- 2095-2106
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2119433625
- Cited by
- 680
- References
- 17
- FWCI
- 59.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.